Aktienanalyse zu Quoin Pharmaceuticals Ltd (QNRX)QNRXQuoin Pharmaceuticals Ltd

Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Quoin Pharmaceuticals Ltd is not a good buy right now due to its current price of $3.65, which is significantly below analyst targets of $12 and $20. The stock has a very low RSI of 28.67, indicating it is oversold, but the company has reported consistent net losses, with a net income of -5,371,042 USD in Q2 2026. The main risk is the company's ongoing financial struggles, as indicated by a 74.08% year-to-date decline in stock price.